How a little-known Swiss medtech is quietly taking market share in a multi-billion-dollar market

Hypothesis

The market often underestimates businesses with genuinely superior products because adoption tends to be gradual before suddenly becoming obvious. Companies that consistently take market share through better customer outcomes can compound for many years, yet are frequently overlooked while they remain relatively small.

Kuros Biosciences is an excellent example of this dynamic.

MagnetOs continues to gain share across the bone graft market: Since its launch, MagnetOs has steadily increased its share of the bone graft market, demonstrating the gradual adoption pattern that often characterises future market leaders.

The Evidence

A differentiated product: Kuros Biosciences develops MagnetOs, an innovative orthobiologic product that stimulates bone regeneration. Initially focused on spinal fusion procedures, the product is now expanding into additional applications including Foot & Ankle surgery.

What makes the business particularly interesting is not simply that it operates within an attractive market, but that published clinical studies suggest MagnetOs delivers favourable  clinical outcomes compared with competing bone graft products. Clinical data indicating positive patient outcomes, alongside potential economic benefits for healthcare providers, have created a compelling proposition that is increasingly resonating with surgeons and hospitals.

For businesses operating in healthcare, sustained product differentiation can become a powerful competitive advantage. As familiarity and confidence grow amongst clinicians, adoption often accelerates over time.

A long runway for growth

Despite its recent success, MagnetOs has only captured a single-digit percentage of its core US market with spine.

We believe this illustrates an important feature of many Future Leaders. Exceptional businesses rarely dominate overnight. Instead, they steadily build market share as customers gain confidence, distribution expands and awareness improves.

With a multi-billion-dollar addressable market still largely untapped, there remains considerable scope for further penetration if current trends continue.

Multiple drivers of future expansion

The opportunity extends well beyond the company's original spinal fusion market.

Kuros continues to broaden the commercial opportunity through:

• expansion into additional surgical indications, including Foot & Ankle;

• continued product innovation, such as settable bone void fillers combined with antibiotics;

• increasing hospital penetration; and

• further international expansion.

  
  

The company has guided to sales growth of more than 35% this year and expects revenues to reach approximately $300–330 million by 2028. While management has understandably adopted a measured tone, we believe the long-term opportunity remains significantly larger given the size of the markets it serves.

Attractive business economics

One of the characteristics we particularly value is the ability for successful businesses to become increasingly profitable as they scale.

Kuros already generates gross margins approaching 90%. While the company is currently investing heavily in infrastructure, including a new manufacturing facility and enterprise systems, these investments should support substantially higher future revenues.

As fixed costs are absorbed and additional sales are generated, a greater proportion of incremental revenue has the potential to translate into profits. Businesses with this combination of strong growth and operating leverage can create significant long-term value for shareholders.

Why this matters

At Goodhart, we are not simply looking for companies that are growing quickly today. We are looking for businesses capable of becoming tomorrow's industry leaders.

Kuros exhibits several of the characteristics we believe define a Future Leader: a differentiated product, expanding market share, attractive long-term economics and a significant opportunity to grow within a large addressable market.

Despite these qualities, the business remains relatively underfollowed by investors, reflecting its modest market capitalisation and limited sell-side research coverage. We believe this disconnect between business progress and market recognition creates an attractive opportunity for long-term investors willing to look beyond today's consensus.

Questions we're asking

• What is the long-term market share that is achievable in the key spine market?

• What new products can be launched, and which new adjacencies can be entered?

• What opportunities are there to redeploy capital now the business has turned free cash flow positive?

• As infrastructure investment moderates, how much operational leverage can the business generate and what is the terminal margin that is achievable?

  
  

What makes this a Future Leader?